CZ20022822A3 - Ve vodě rozpustná proléčiva azolových sloučenin - Google Patents

Ve vodě rozpustná proléčiva azolových sloučenin Download PDF

Info

Publication number
CZ20022822A3
CZ20022822A3 CZ20022822A CZ20022822A CZ20022822A3 CZ 20022822 A3 CZ20022822 A3 CZ 20022822A3 CZ 20022822 A CZ20022822 A CZ 20022822A CZ 20022822 A CZ20022822 A CZ 20022822A CZ 20022822 A3 CZ20022822 A3 CZ 20022822A3
Authority
CZ
Czechia
Prior art keywords
compound
pharmaceutically acceptable
hydroxy
formula
acceptable salt
Prior art date
Application number
CZ20022822A
Other languages
Czech (cs)
English (en)
Inventor
Yasutsugu Ueda
John D. Matiskella
Jerzy Golik
Thomas W. Hudyma
Chung-Pin Chen
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of CZ20022822A3 publication Critical patent/CZ20022822A3/cs

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503Five-membered rings
    • C07F9/6506Five-membered rings having the nitrogen atoms in positions 1 and 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6515Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having three nitrogen atoms as the only ring hetero atoms
    • C07F9/6518Five-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Polymerization Catalysts (AREA)
CZ20022822A 2000-01-20 2001-01-16 Ve vodě rozpustná proléčiva azolových sloučenin CZ20022822A3 (cs)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17716900P 2000-01-20 2000-01-20
US24996900P 2000-11-20 2000-11-20

Publications (1)

Publication Number Publication Date
CZ20022822A3 true CZ20022822A3 (cs) 2003-02-12

Family

ID=26873001

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ20022822A CZ20022822A3 (cs) 2000-01-20 2001-01-16 Ve vodě rozpustná proléčiva azolových sloučenin

Country Status (22)

Country Link
US (1) US6362172B2 (https=)
EP (1) EP1284737B1 (https=)
JP (1) JP3766804B2 (https=)
KR (1) KR100748299B1 (https=)
CN (1) CN1178665C (https=)
AT (1) ATE300946T1 (https=)
AU (1) AU782177C (https=)
BR (1) BR0107618A (https=)
CA (1) CA2397734C (https=)
CZ (1) CZ20022822A3 (https=)
DE (1) DE60112433T2 (https=)
DK (1) DK1284737T5 (https=)
ES (1) ES2247131T3 (https=)
HU (1) HU229226B1 (https=)
IL (2) IL150798A0 (https=)
MX (1) MXPA02007120A (https=)
NO (1) NO330352B1 (https=)
NZ (1) NZ519354A (https=)
PL (1) PL206024B1 (https=)
PT (1) PT1284737E (https=)
RU (1) RU2266909C2 (https=)
WO (1) WO2001052852A1 (https=)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6448401B1 (en) * 2000-11-20 2002-09-10 Bristol-Myers Squibb Company Process for water soluble azole compounds
HUP0303249A3 (en) 2001-02-22 2007-03-28 Sankyo Co Water-soluble triazole fungicide compounds and pharmaceutical compositions containing them
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
ES2445208T3 (es) 2002-07-29 2014-02-28 Rigel Pharmaceuticals, Inc. Compuestos de 2,4-pirimidindiamina para uso en métodos para tratar o prevenir enfermedades autoinmunitarias
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
BRPI0413018B8 (pt) 2003-07-30 2021-05-25 Rigel Pharmaceuticals Inc composto, e, uso de um composto
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE602006010979D1 (de) 2005-01-19 2010-01-21 Rigel Pharmaceuticals Inc Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen
JO2691B1 (en) * 2005-05-03 2013-03-03 ايساي آر آند دي مانجمنت كو.، ليمتد Monolysine salts for azole compounds
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
ES2432360T3 (es) * 2005-12-20 2013-12-03 Eisai R&D Management Co., Ltd. Procedimiento para la producción de profármaco de azol soluble en agua
EP2043446A2 (en) * 2006-02-08 2009-04-08 Phibro-Tech Inc. Biocidal azole emulsion concentrates having high active ingredient content
CN101389333A (zh) 2006-02-22 2009-03-18 卫材R&D管理有限公司 稳定化药物组合物
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
KR101452915B1 (ko) 2006-05-04 2014-10-21 베링거 인겔하임 인터내셔날 게엠베하 다형태
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
RU2010151953A (ru) 2008-05-20 2012-06-27 Ньюроджесэкс, Инк. (Us) Карбонатные продукты и способы их применения
KR101698028B1 (ko) 2008-05-20 2017-01-26 노이로제스엑스, 인코포레이티드 수용성 아세트아미노펜 유사체
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
CA2736421A1 (en) 2008-09-10 2010-03-18 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
JP2012512848A (ja) 2008-12-23 2012-06-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 有機化合物の塩の形態
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
KR20240090632A (ko) 2009-11-27 2024-06-21 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 dpp-iv 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
CA3070513C (en) 2010-05-05 2023-01-03 Boehringer Ingelheim International Gmbh A dpp-4 inhibitor for use in treatment of skin-alterations or necrosis
KR20130093012A (ko) 2010-06-24 2013-08-21 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
WO2012060448A1 (ja) 2010-11-05 2012-05-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗真菌剤としての併用医薬組成物
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
EP2651450B1 (en) * 2010-12-16 2015-12-16 Borje S. Andersson Azole pharmaceutical formulations for parenteral administration and methods for preparing and using the same as treatment of diseases sensitive to azole compounds
BR112013033239A2 (pt) 2011-06-22 2016-09-06 Vyome Biosciences pró-farmácos de conjugado baseado em atifungicos e antibacterianos
DK2731947T3 (en) 2011-07-15 2019-04-23 Boehringer Ingelheim Int SUBSTITUTED DIMERIC QUINAZOLINE DERIVATIVE, PREPARATION AND USE thereof IN PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF TYPE I AND TYPE II DIABETES
US8426450B1 (en) * 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
ES2774267T3 (es) 2012-01-20 2020-07-20 Mycovia Pharmaceuticals Inc Compuestos inhibidores de metaloenzimas
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
KR102044734B1 (ko) 2012-04-20 2019-11-15 에자이 알앤드디 매니지먼트 가부시키가이샤 캡슐 제형
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013171166A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp-4 inhibitor for use in the treatment of sirs and/or sepsis
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
MX2015016675A (es) 2013-06-04 2016-07-15 Vyome Biosciences Pvt Ltd Particulas recubiertas y composiciones que comprenden las mismas.
ES2784307T3 (es) 2014-01-29 2020-09-24 Vyome Therapeutics Ltd Besifloxacina para el tratamiento del acné resistente
EP3110449B1 (en) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
CN104926870B (zh) * 2014-03-21 2017-02-08 合肥久诺医药科技有限公司 一种福司氟康唑的精制方法
TW201718495A (zh) * 2015-07-28 2017-06-01 貝塔貓製藥股份有限公司 蒽-9, 10-二酮二肟化合物前驅藥及其用途
EP4233840A3 (en) 2016-06-10 2023-10-18 Boehringer Ingelheim International GmbH Combinations of linagliptin and metformin
CN107501255B (zh) * 2017-09-12 2019-08-23 成都施贝康生物医药科技有限公司 一种艾沙康唑衍生物及其用途
CN108676031A (zh) * 2018-05-29 2018-10-19 重庆威鹏药业有限公司 水溶性三唑类抗真菌膦酸化合物及其制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8819308D0 (en) * 1988-08-13 1988-09-14 Pfizer Ltd Triazole antifungal agents
GB9002375D0 (en) * 1990-02-02 1990-04-04 Pfizer Ltd Triazole antifungal agents
CA2111527C (en) 1992-12-24 2000-07-18 Jerzy Golik Phosphonooxymethyl ethers of taxane derivatives
CA2129288C (en) 1993-08-17 2000-05-16 Jerzy Golik Phosphonooxymethyl esters of taxane derivatives
PL181193B1 (pl) 1993-12-21 2001-06-29 Schering Corp Nowe pochodne tetrahydrofuranowe o działaniu przeciwgrzybicznym, kompozycja farmaceutyczna do leczenia infekcji grzybiczych oraz sposób wytwarzania tych związków
US5714490A (en) * 1993-12-21 1998-02-03 Schering Corporation Tetrahydrofuran antifungals
SG48386A1 (en) 1994-01-24 1998-04-17 Janssen Pharmaceutica Nv Watersoluble azole antifungals
NZ270418A (en) 1994-02-07 1997-09-22 Eisai Co Ltd Polycyclic triazole & imidazole derivatives, antifungal compositions
HUP9701690A3 (en) 1995-06-02 1998-04-28 Schering Corp Kenilwort Tetrahydrofuran derivatives as antifungals and pharmaceutical compositions containing the same
TW354293B (en) * 1995-06-06 1999-03-11 Bristol Myers Squibb Co Prodrugs of paclitaxel derivatives
GB9602080D0 (en) 1996-02-02 1996-04-03 Pfizer Ltd Pharmaceutical compounds
EP0829478A3 (en) 1996-09-09 1998-03-25 F. Hoffmann-La Roche Ag N-Benzylimidazolium and N-benzyltriazolium derivatives, their preparation and their use as antifungal and antimycotic agents
PT1056754E (pt) 1998-01-29 2004-03-31 Bristol Myers Squibb Co Derivados fosfatados de 1,3,4-oxadiazolona de diarilo
US5883097A (en) 1998-04-16 1999-03-16 Schering Corporation Soluble azole antifungal salt
US6204257B1 (en) 1998-08-07 2001-03-20 Universtiy Of Kansas Water soluble prodrugs of hindered alcohols
AU1915500A (en) * 1998-11-20 2000-06-13 Bristol-Myers Squibb Company Water soluble prodrugs of azole compounds
US6448401B1 (en) * 2000-11-20 2002-09-10 Bristol-Myers Squibb Company Process for water soluble azole compounds

Also Published As

Publication number Publication date
NO20023468L (no) 2002-07-29
DE60112433D1 (de) 2005-09-08
ES2247131T3 (es) 2006-03-01
WO2001052852A1 (en) 2001-07-26
DK1284737T5 (da) 2007-09-24
BR0107618A (pt) 2002-11-12
KR100748299B1 (ko) 2007-08-09
PL206024B1 (pl) 2010-06-30
EP1284737A1 (en) 2003-02-26
HU229226B1 (en) 2013-09-30
RU2266909C2 (ru) 2005-12-27
NO330352B1 (no) 2011-04-04
DE60112433T2 (de) 2006-05-18
EP1284737A4 (en) 2003-03-19
CN1178665C (zh) 2004-12-08
AU782177C (en) 2007-10-18
ATE300946T1 (de) 2005-08-15
CN1395485A (zh) 2003-02-05
AU2948501A (en) 2001-07-31
JP2003520235A (ja) 2003-07-02
CA2397734A1 (en) 2001-07-26
CA2397734C (en) 2010-08-17
PL356164A1 (en) 2004-06-14
NO20023468D0 (no) 2002-07-19
DK1284737T3 (da) 2005-11-28
HUP0204405A3 (en) 2005-02-28
MXPA02007120A (es) 2003-01-28
KR20020070492A (ko) 2002-09-09
PT1284737E (pt) 2005-11-30
EP1284737B1 (en) 2005-08-03
JP3766804B2 (ja) 2006-04-19
US20010041691A1 (en) 2001-11-15
HUP0204405A2 (en) 2003-05-28
IL150798A0 (en) 2003-02-12
US6362172B2 (en) 2002-03-26
AU782177B2 (en) 2005-07-07
IL150798A (en) 2006-08-01
NZ519354A (en) 2004-05-28

Similar Documents

Publication Publication Date Title
CZ20022822A3 (cs) Ve vodě rozpustná proléčiva azolových sloučenin
US6448401B1 (en) Process for water soluble azole compounds
AU2002213317A1 (en) Improved process for water soluble azole compounds
ZA200709127B (en) Mono-lysine salts of azole compounds
WO1999061017A1 (en) Water-soluble prodrugs of azole compounds
ZA200204332B (en) Water soluble prodrugs of azole compounds.
HK1117502B (en) Mono-lysine salts of azole compounds